WO2002072094A3 - Verwendung neuroaktiver substanzen und deren kombination zur behandlung der parkinsonschen krankheit - Google Patents

Verwendung neuroaktiver substanzen und deren kombination zur behandlung der parkinsonschen krankheit Download PDF

Info

Publication number
WO2002072094A3
WO2002072094A3 PCT/EP2002/002571 EP0202571W WO02072094A3 WO 2002072094 A3 WO2002072094 A3 WO 2002072094A3 EP 0202571 W EP0202571 W EP 0202571W WO 02072094 A3 WO02072094 A3 WO 02072094A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
parkinsons disease
combinations
neuroactive substances
substance
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2002/002571
Other languages
English (en)
French (fr)
Other versions
WO2002072094A2 (de
Inventor
Ralph Dawirs
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to EP02724212A priority Critical patent/EP1377294B1/de
Priority to US10/469,833 priority patent/US20040147613A1/en
Priority to KR10-2003-7011884A priority patent/KR20040007464A/ko
Priority to DE50206139T priority patent/DE50206139D1/de
Priority to JP2002571053A priority patent/JP2004526723A/ja
Priority to AU2002254935A priority patent/AU2002254935A1/en
Publication of WO2002072094A2 publication Critical patent/WO2002072094A2/de
Publication of WO2002072094A3 publication Critical patent/WO2002072094A3/de
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4515—Non condensed piperidines, e.g. piperocaine having a butyrophenone group in position 1, e.g. haloperidol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Die Erfindung betrifft eine Verwendung einer ersten Substanz, welche postsynaptische, für einen bestimmten Neurotransmitter spezifische Rezeptoren zumindest teilweise blockiert, und einer zweiten Substanz, welche eine Deafferentierung der auf den Neurotransmitter zurückzuführenden Innervation initiiert beziehungsweise begünstigt, zur Behandlung der Parkinsonschen Krankheit beziehungsweise zum Herstellen eines Arzneimittels beziehungsweise einer Arzneimittelkombination zur Behandlung der Parkinsonschen Krankheit. Die Erfindung betrifft ferner eine Arzneimittelkombination.
PCT/EP2002/002571 2001-03-09 2002-03-08 Verwendung neuroaktiver substanzen und deren kombination zur behandlung der parkinsonschen krankheit Ceased WO2002072094A2 (de)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EP02724212A EP1377294B1 (de) 2001-03-09 2002-03-08 Verwendung neuroaktiver substanzen und deren kombination zur behandlung der parkinsonschen krankheit
US10/469,833 US20040147613A1 (en) 2001-03-09 2002-03-08 Use of neuroactive substances for the treatment of parkinsons disease and pharmaceutical combination
KR10-2003-7011884A KR20040007464A (ko) 2001-03-09 2002-03-08 파킨슨병을 치료하기 위한 신경활성물질의 용도 및약제학적 조합물
DE50206139T DE50206139D1 (de) 2001-03-09 2002-03-08 Verwendung neuroaktiver substanzen und deren kombination zur behandlung der parkinsonschen krankheit
JP2002571053A JP2004526723A (ja) 2001-03-09 2002-03-08 パーキンソン病治療用の神経活性物質の使用および併用薬
AU2002254935A AU2002254935A1 (en) 2001-03-09 2002-03-08 Use of neuroactive substances and combinations thereof for the treatment of parkinsons disease

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10111486.9 2001-03-09
DE10111486A DE10111486A1 (de) 2001-03-09 2001-03-09 Verwendung einer oder mehrerer neuroaktiver Substanzen zur Behandlung der Parkinsonschen Krankheit

Publications (2)

Publication Number Publication Date
WO2002072094A2 WO2002072094A2 (de) 2002-09-19
WO2002072094A3 true WO2002072094A3 (de) 2003-01-23

Family

ID=7676934

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/002571 Ceased WO2002072094A2 (de) 2001-03-09 2002-03-08 Verwendung neuroaktiver substanzen und deren kombination zur behandlung der parkinsonschen krankheit

Country Status (11)

Country Link
US (1) US20040147613A1 (de)
EP (1) EP1377294B1 (de)
JP (1) JP2004526723A (de)
KR (1) KR20040007464A (de)
AT (1) ATE320810T1 (de)
AU (1) AU2002254935A1 (de)
DE (2) DE10111486A1 (de)
DK (1) DK1377294T3 (de)
ES (1) ES2261663T3 (de)
PT (1) PT1377294E (de)
WO (1) WO2002072094A2 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007016190A2 (en) * 2005-07-28 2007-02-08 Duke University Antiparkinsonian action of phenylisopropylamines
BR112012008193A2 (pt) * 2009-07-31 2016-03-01 Clera Inc composições compreendendo um inibidor de receptor dopaminérgico d2, bem como o uso do preferido inibidor

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2825322A1 (de) * 1977-06-30 1979-01-11 Byk Gulden Lomberg Chem Fab Alkylsubstituierte piperidin-n- oxide, verfahren zu ihrer herstellung, ihre verwendung und sie enthaltende arzneimittel
US5952501A (en) * 1993-01-06 1999-09-14 Neurogen Corporation Certain tricyclic substituted diazabicylo 3.2.1! octane derivatives
WO2001012236A2 (en) * 1999-08-18 2001-02-22 The General Hospital Corporation Methods, compositions and kits for promoting recovery from damage to the central nervous system

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5602150A (en) * 1992-10-02 1997-02-11 Research Foundation For Mental Hygiene, Inc. Treatment of central nervous system disorders associated with psychotic behavior and dementia with a combination of neuroleptic drugs and taurine, or derivatives thereof, to prevent the development of tardive dyskinesia
JPH10502923A (ja) * 1994-07-15 1998-03-17 パーデュー・リサーチ・ファンデーション ジヒドレキシジンおよびその置換類似体の光学活性異性体
KR20000057303A (ko) * 1996-12-24 2000-09-15 후지야마 아키라 아미노피페라진 유도체의 신규 용도
CA2315092A1 (en) * 1997-12-31 1999-07-08 Direct Therapeutics, Inc. Method for tissue perfusion

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2825322A1 (de) * 1977-06-30 1979-01-11 Byk Gulden Lomberg Chem Fab Alkylsubstituierte piperidin-n- oxide, verfahren zu ihrer herstellung, ihre verwendung und sie enthaltende arzneimittel
US5952501A (en) * 1993-01-06 1999-09-14 Neurogen Corporation Certain tricyclic substituted diazabicylo 3.2.1! octane derivatives
WO2001012236A2 (en) * 1999-08-18 2001-02-22 The General Hospital Corporation Methods, compositions and kits for promoting recovery from damage to the central nervous system

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
HUEBERT N D ET AL: "THE EFFECTS OF SOME STIMULANTS AND ANTI PSYCHOTIC DRUGS ON URINARY UNCONJUGATED TYRAMINE LEVELS IN THE RAT", RESEARCH COMMUNICATIONS IN CHEMICAL PATHOLOGY AND PHARMACOLOGY, vol. 22, no. 1, 1978, EN, pages 73 - 82, XP009000120, ISSN: 0034-5164 *

Also Published As

Publication number Publication date
JP2004526723A (ja) 2004-09-02
EP1377294B1 (de) 2006-03-22
KR20040007464A (ko) 2004-01-24
EP1377294A2 (de) 2004-01-07
DE50206139D1 (de) 2006-05-11
PT1377294E (pt) 2006-08-31
AU2002254935A1 (en) 2002-09-24
ATE320810T1 (de) 2006-04-15
DK1377294T3 (da) 2006-07-24
DE10111486A1 (de) 2002-10-02
WO2002072094A2 (de) 2002-09-19
US20040147613A1 (en) 2004-07-29
ES2261663T3 (es) 2006-11-16

Similar Documents

Publication Publication Date Title
MXPA03005284A (es) Nuevo procedimiento para la sintesis de fenilamida del acido 5-(4-flourofenil) -1-[2-((2r, 4r)-4-hidroxi -6-oxotetrahidro -piran-2-il) -etil]-2-isopropil -4-fenil-1h -pirrol-3-carboxilico.
ZA200401015B (en) Compounds effecting glucokinase.
PL375874A1 (pl) Wodne kompozycje farmaceutyczne 2,6-diizopropylofenolu
IT1319201B1 (it) Farmaci per il diabete.
WO2003037863A3 (de) Substituierte indole, verfahren zu deren herstellung und deren verwendung zur schmerzbekämpfung
AP2004003066A0 (en) Pharmaceutical compositions based on azetidine derivatives.
WO2004073615A8 (en) Deazaflavin compounds and methods of use thereof
DK1958938T3 (da) Fremgangsmåde til fremstilling af 10,11-dihydro-10-oxo-5H-dibenz[b,f]azepin-5-carboxamid
WO2004087880A3 (en) Compounds and their use to treat diabetes and related disorders
PT1355906E (pt) Derivados de 2h-1-benzopirano processos para a sua preparacao e as suas composicoes farmaceuticas
MA26397A1 (fr) Protege-orteils, particulierement pour chaussures de securite.
WO2002072094A3 (de) Verwendung neuroaktiver substanzen und deren kombination zur behandlung der parkinsonschen krankheit
AU2002241326A1 (en) Remedies for psychoneurosis
NO20064783L (no) Opplosningstabeletter med licarbazepin
ZA200409081B (en) Shaft preheater.
BR0208063B1 (pt) processo para a preparaÇço de 2,6-dialquilmorfolinas n-substituÍdas.
WO2004078142A3 (en) Compositions and methods for preventing and treating endotoxin-related diseases and conditions
WO2003005970A3 (en) Carvedilol polymorph
ZA200205835B (en) Compounds useful for the treatment or prevention of a disease mediated by the alpha-2B-adrenoceptor.
WO2004105785A3 (en) Use of pam
AU2003275360A1 (en) Aqueous 2,6-diisopropylphenol pharmaceutical compositions
ZA200308097B (en) Substituted sulfonamide compounds, process for their use as medicament for the treatment of CNS disorders, obesity and type II diabetes.
AU2002346836A1 (en) Method for the production of chiral, non-racemic 5-substituted gamma-butyrolactones
WO2005021005A3 (en) Process for the preparation of 1,4-benzodiazepine derivatives
ZA200400480B (en) A synergistic pharmaceutical combination for the prevention or treatment of diabetes.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002571053

Country of ref document: JP

Ref document number: 1020037011884

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2002724212

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002724212

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10469833

Country of ref document: US

WWG Wipo information: grant in national office

Ref document number: 2002724212

Country of ref document: EP